How to account for stock-based compensation: the grant date is the only part you control

The short version

• Under ASC 718, an equity-classified award is measured once, at grant-date fair value, and that cost is spread over the vesting period. Debit stock compensation expense, credit additional paid-in capital. If the stock triples afterwards, the expense does not move. (SEC, SAB Topic 14)
• The grant date is not the day you promised the equity. It arrives only when all required approvals have been obtained and both sides understand the key terms. An offer letter is a promise. A signed board consent is a grant.
• An option priced below fair market value on its grant date is a discounted option, and the Section 409A consequences of that fall primarily on your employee. The company keeps its own reporting and withholding exposure, but the income recognition and penalty tax land on the recipient. The usual cause is a strike price quoted months before the board approval that legally created the grant.
• Almost every other question here is a policy election your accountant makes once and applies consistently. Grant timing is the only input that is entirely yours, and it is the one that determines whether the rest of the file holds up.

Your offer letter did not grant anything

January. You send an offer to an engineer. Forty thousand options, four year vest, one year cliff, strike price at the current 409A of $1.20. She accepts and starts on February 3.

The board consent joins the pile of things to get signed. In April you close a round and the new 409A comes back at $2.40. In June somebody clearing out the folder finally circulates the consent, and the option agreement goes out with $1.20 on it, because that is the number in the offer letter and nobody wants to reopen a conversation from five months ago.

The agreement is dated June. The strike price is dated January. The valuation everyone will test it against is dated April.

A grant is a board action, and nothing you did before it counts

You think of the equity as granted in January because that is when you decided, when you said it out loud, and when she agreed to join for it. Accounting does not see any of that.

ASC 718 measures an award on its grant date, and the grant date arrives only when a specific set of conditions holds: you and the recipient have reached a mutual understanding of the key terms, every approval your governance documents require has actually been obtained, the company has become contingently obligated to issue the equity, and the recipient starts to be affected by movements in the share price. The SEC's guidance is explicit that the required approvals are part of that test. (SEC)

So the grant date is June. Not because anyone is being pedantic, but because until the board acted, the company was not obligated to anything and could have changed the terms.

This has a consequence you should expect to see in your own numbers. Your engineer has been working since February, and that service does not go unrecorded. When someone starts providing service before the grant date, cost is generally accrued from the service inception date using an estimated fair value, then trued up once the real grant-date measurement exists. Your P&L carries four months of expense for an award that did not formally exist.

That is the accounting version. The expensive version is about the price.

The gap costs your employee, not you

An option granted with an exercise price below the fair market value of the stock on its grant date is a discounted option. Discounted options are where Section 409A penalties live, and they land on the recipient: potential income recognition before the option is ever exercised, plus an additional penalty tax on top of ordinary rates.

Read that back against the scene. You promised $1.20 in good faith. The board granted in June, after a valuation that came back at $2.40. Your engineer now holds an option that a tax authority may treat as discounted by $1.20 a share, and the first she will hear about it is from her own accountant, or from a diligence process, or from a repricing conversation nobody wants to have.

The same facts return later in a different costume. Companies heading toward an IPO get asked about cheap stock, where auditors look back at grants issued below fair value and require additional compensation cost to be recognized. The grants that trigger it are rarely deliberate. They are almost always the ones where the paperwork trailed the promise across a valuation event.

You cannot control whether a 409A moves between an offer and an approval. It moves when it moves, usually because you raised, which is a good problem. What you control is the length of the gap.

Approve grants on a fixed cadence. Monthly or quarterly, in a real board or committee action, batched. The cost of an unsigned consent is invisible right up until it is priced.

Quote the mechanism in offer letters, not the number. "Strike price will be the fair market value determined by the board on the date of grant" survives a valuation change. "$1.20" does not.

Get a new 409A before the grants, not after. If a financing, a major customer, or a secondary is in flight, the valuation is going to move. Grant after it lands, or accept that the approval you sign is the one being tested.

Keep one grant register, and make the consent date the authoritative field. Not the offer date, not the start date. Cap table, option ledger, and accounting all need to be reading the same date, and it is the one on the consent.

Fair value is measured once, and then you stop thinking about it

Once the grant date is fixed, valuation follows from it.

An RSU generally starts from the fair value of the underlying share. An option needs a model, because its value depends on volatility, expected term, the risk-free rate, and the exercise price rather than on a share price alone. The SEC does not mandate a particular model, only that the method be consistent with the fair value objective, grounded in established financial economics theory, and able to reflect the substantive terms of the award. 

At a private company two of those inputs have no observable answer, since there is no traded price and no volatility history. Both come out of the same valuation analysis you are already paying for.

Then it is finished. For an equity-classified award, the grant-date number is permanent. Your stock can 10x or go to zero and the compensation expense recognized over the vesting period does not change, because the accounting measured what you handed over on the day you handed it over.

The one thing that reopens it is changing the deal itself. Reprice the strike, extend the exercise window, or accelerate vesting, and you have modified the award, which forces a fresh measurement. Market movement does nothing; amending the terms does.

One exception is worth knowing by name. A cash-settled or otherwise liability-classified award is not fixed at grant and forgotten. It gets re-measured at every reporting date until it settles, so the number tracks your share value for as long as the award lives. Public companies mark it to fair value. A private company can elect intrinsic value instead, though the standard treats fair value as the preferable measure. Either way, this is the one award that does not behave like the rest of your plan, so if you have promised someone a cash payment tied to share value, say so before it gets booked.

Four questions to ask your accountant, once

Everything left is a policy election. You are not going to make these calls, but you should know they were made deliberately rather than by whichever template opened first.

Which attribution method are we using for graded vesting? Straight-line over the full service period, or accelerated by tranche. Both are permitted and they produce noticeably different expense in the early years, which matters if anyone is reading your margins.

What is our forfeiture policy? Estimate up front, or recognize as they occur. Either is fine. Changing it quietly month to month is not.

Is the expense sitting in the same line as the salaries? Engineering grants belong in R&D, sales grants in sales and marketing, because share-based compensation should follow the same income statement lines as cash compensation for the same people. Everything swept into G&A is the most common presentation error and it distorts every margin you report.

What is the gap between our book expense and our tax deduction? Book expense follows the vesting period. The deduction follows a tax event, usually exercise or settlement, at values on that later date. They get reconciled, not equated, and the answer changes again the moment an award crosses a border.

Non-cash does not mean free

Stock compensation is added back to net income on the cash flow statement, which is where founders learn to file it mentally as an accounting artifact.

It is a real cost recorded in a currency the income statement cannot express. The expense line says $10,000. What actually left the company was a claim on its future equity, and the size of that claim shows up on the cap table, not the bank statement. The accounting is a shadow of the transaction rather than the transaction.

Which is why the grant paperwork is worth your attention and the journal entry is not. The entry describes what happened. The consent decides it.

How this looks in practice

Most of our work here sits underneath the argument in this post. Keeping the grant register current, chasing the consent that turns a promise into a grant, building the vesting schedules the expense is calculated from, and asking what a strike price was set against before the answer becomes a footnote in a diligence request.

It is clerical work, and it is meant to be. The best version of it produces nothing dramatic. It produces a company whose option ledger, cap table, and income statement all describe the same events, which is the entire point.

The takeaway

There are four questions in stock compensation accounting. What was granted, when was it actually granted, what was it worth that day, and does the credit go to equity or to a liability.

Three of them have technical answers you can buy. The second one does not, because equity gets promised in conversations and granted in paperwork, and only the paperwork exists as far as anyone else is concerned.

Sign the consent while the valuation you quoted is still the valuation in force. Everything downstream is arithmetic.

FAQs

When is the grant date for a startup stock option?

The grant date is the date the company and the recipient reach a mutual understanding of the key terms and all required approvals have been obtained, at which point the company is contingently obligated to issue the equity and the recipient begins to be affected by changes in the share price. For most startups this is the date the board or compensation committee signs the consent, not the date the offer letter went out and not the employee's start date. It matters because grant-date fair value is what the entire compensation expense is measured from, and because the exercise price gets tested against fair market value on that date.

What happens if you promise a strike price and grant the options months later?

If the company's 409A valuation increases between the promise and the board approval, honouring the originally quoted strike price produces an option granted below fair market value on its grant date. That creates Section 409A exposure for the recipient, potentially including income recognition before exercise plus a penalty tax, and it can resurface as a cheap stock issue if the company later prepares for an IPO. The fix is preventive: batch grant approvals on a regular basis, and describe the strike price in offer letters as the fair market value determined on the grant date instead of quoting a specific number.

Does a pre-revenue startup have to record stock-based compensation expense?

Yes, if it reports under U.S. GAAP. ASC 718 applies regardless of revenue, profitability, or whether shares are publicly traded, so a startup granting options is recognizing compensation cost even though no cash moves. The difficulty for a private company is the inputs rather than the obligation, because there is no observable share price and no historical volatility, so both are estimated as part of the same valuation work supporting the 409A.

What is the journal entry for stock-based compensation?

For an equity-classified award you debit stock-based compensation expense and credit additional paid-in capital each period, for the portion of the total grant-date fair value attributable to that period. An award with $40,000 of grant-date fair value vesting over four years produces roughly $10,000 of expense a year. The expense should appear in the same income statement line as cash compensation for those same people, so engineering grants sit in research and development rather than in general and administrative.

Is stock-based compensation a cash expense?

No. It is non-cash, so under the indirect method it gets added back to net income when reconciling to operating cash flow. That does not make it costless, because the company is paying in ownership instead of cash, and the price of that payment appears on the cap table rather than on the bank statement. Read the expense line and the dilution together.

Do I need to expense options for advisors and contractors too?

Generally yes. ASU 2018-07 aligned the measurement of most nonemployee share-based payments with the employee model, so awards to advisors, contractors, and other service providers are measured at grant-date fair value and recognized as the services are received. (FASB) The grant date question applies identically, which means advisor grants approved long after the advisory agreement was signed carry the same pricing risk as employee grants.